| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
Paricalcitol-D6 is the deuterated form of Paricalcitol(Zemplar), which is a novel and potent vitamin D receptor agonist developed by Abbott Laboratories under the trade name Zemplar and is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
| Targets |
Vitamin D receptor (VDR).
|
|---|---|
| ln Vitro |
Paricalcitol-D6 is expected to have essentially identical biological activity to paricalcitol, which is a VDR agonist that binds to the vitamin D receptor and regulates gene expression; it lowers parathyroid hormone (PTH) levels by binding to VDR in the parathyroid glands and upregulates VDR-responsive genes; in leukemic cells, it upregulates cyclin-dependent kinase inhibitors and the tumor suppressor PTEN.
|
| ln Vivo |
As a deuterated standard, Paricalcitol-D6 is not intended for therapeutic use; however, non-deuterated paricalcitol is an approved drug for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease; it is active in vivo with demonstrated efficacy in clinical settings.
|
| Enzyme Assay |
Binding affinity for the vitamin D receptor is typically measured by competitive radioligand binding assays using recombinant VDR protein; Paricalcitol-D6 is incubated with 3H-1,25-dihydroxyvitamin D3 in the presence of VDR; bound radioactivity is separated, and the displacement curve is used to calculate Ki or IC50; these assays are performed to confirm that the D6 label does not alter receptor binding.
|
| Cell Assay |
Paricalcitol-D6 is used as a stable isotope-labeled internal standard in LC-MS/MS (liquid chromatography-tandem mass spectrometry) bioanalytical methods for the quantification of paricalcitol in biological matrices (plasma, urine, tissue homogenates); the D6-labeled compound is spiked into samples, and the ratio of paricalcitol to Paricalcitol-D6 is measured for accurate quantitation.
|
| Animal Protocol |
Not applicable for Paricalcitol-D6 as a D6 standard; for paricalcitol, in vivo efficacy studies are performed in 5/6-nephrectomized rats (chronic kidney disease model) to assess PTH lowering; in humans, clinical trials have established its efficacy and safety profile.
|
| ADME/Pharmacokinetics |
Paricalcitol-D6 is an analytical standard with the same PK properties as non-deuterated paricalcitol; non-deuterated paricalcitol: oral administration; bioavailable; metabolized by CYP24A1 and other vitamin D-metabolizing enzymes; excreted primarily in bile and feces; plasma half-life is approximately 5-7 hours.
|
| Toxicity/Toxicokinetics |
Paricalcitol-D6 is a labeled standard with no independent toxicity; non-deuterated paricalcitol has an established clinical safety profile: common adverse effects include hypercalcemia, nausea, vomiting, and hypersensitivity; it is contraindicated in patients with hypercalcemia or vitamin D toxicity.
|
| References |
|
| Additional Infomation |
Paricalcitol-D6 is not a therapeutic agent; it is a stable isotope-labeled analytical standard used exclusively for research and quality control purposes; it is not approved for clinical use; it is used to support bioequivalence studies, pharmacokinetic studies, and drug metabolism research for paricalcitol; the parent drug paricalcitol (Zemplar®) is approved by FDA and EMA for secondary hyperparathyroidism in chronic kidney disease.
|
| Molecular Formula |
C27H44O3
|
|---|---|
| Molecular Weight |
422.673439025879
|
| Exact Mass |
422.366
|
| CAS # |
2070009-67-3
|
| PubChem CID |
66577066
|
| Appearance |
White to off-white solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
OC(C([2H])([2H])[2H])(C([2H])([2H])[2H])[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3/C[C@H](C[C@@H](C/3)O)O)/CCC[C@]12C
|
| InChi Key |
BPKAHTKRCLCHEA-OYAGBYDGSA-N
|
| InChi Code |
InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1/i3D3,4D3
|
| Chemical Name |
(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,2R,5S)-7,7,7-trideuterio-6-hydroxy-5-methyl-6-(trideuteriomethyl)hept-3-en-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~236.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3659 mL | 11.8296 mL | 23.6591 mL | |
| 5 mM | 0.4732 mL | 2.3659 mL | 4.7318 mL | |
| 10 mM | 0.2366 mL | 1.1830 mL | 2.3659 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
